Beauty Health Earnings Call: Profits Up, Sales Strain

Beauty Health Company ((SKIN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Beauty Health Company’s latest earnings call painted a nuanced picture for investors. Management delivered a clear message of financial discipline and margin strength, with EBITDA and cash metrics surpassing expectations. Yet, they also acknowledged revenue pressure, softer device placements and structural macro and competitive headwinds, framing 2026 as a stabilization year ahead of a hoped‑for recovery in 2027.

Adjusted EBITDA Outperformance

Beauty Health posted adjusted EBITDA of $8.5 million in Q1, up 17% year over year and equating to a 13.1% margin. The figure landed well ahead of the prior guidance range of $3.5 million to $5.5 million, underscoring strong cost control and operating leverage despite the weaker top line.

Strong Adjusted Gross Margin

Adjusted gross margin edged up to 72.2% in Q1 from 71.9% a year earlier, showing resilience even as revenue declined. Management highlighted robust pricing and product mix as drivers, though they cautioned that certain one‑time benefits mean margins should normalize lower in coming quarters.

Improved Profitability and Cost Discipline

GAAP operating expenses fell sharply to $46.2 million from $60.6 million, driven by lower sales and marketing, G&A and legal costs. This discipline helped narrow the net loss to $6.6 million from $10.1 million, signaling progress toward sustainable profitability while still funding key initiatives.

Growing Installed Base and Reduced Churn

The active installed base expanded to 36,400 systems, up 4% year over year, demonstrating continued penetration of HydraFacial devices. At the same time, device churn dropped 40%, a notable improvement that points to better provider retention and successful reactivation of previously inactive accounts.

Strong Cash Position and Manageable Debt

The company ended the quarter with $204.4 million in cash, cash equivalents and restricted cash, providing a significant liquidity cushion. Management expressed confidence in addressing the approximately $103 million debt maturity due in October 2026, supported by current cash flow expectations and modest planned CapEx.

Maintained Full-Year Adjusted EBITDA Guidance

Despite cutting revenue expectations, Beauty Health reaffirmed its full‑year adjusted EBITDA outlook of $35 million to $45 million. That stance suggests the company expects continued margin strength and operational efficiency to offset top‑line softness, a key point for investors focused on earnings quality.

Active Innovation and Board Strengthening

Innovation remains central, with a full booster portfolio overhaul underway and a relaunch of Keravive, now branded HydraScalp, slated for later this quarter. A clinically backed booster is expected in Q4 and a next‑generation Hydrafacial device is being developed for a targeted 2028 launch, supported by three new independent directors with strong medtech and aesthetics backgrounds.

Revenue Decline and Guidance Reduction

Total net sales were $64.9 million in Q1, down 6.7% year over year but in line with prior guidance, reflecting pressures across both devices and consumables. Full‑year revenue guidance was trimmed to a range of $280 million to $295 million from $285 million to $305 million, roughly a 2.5% reduction or about $7.5 million at the midpoint.

Device Placements Softness

Delivery systems revenue fell 8.3% to $18.5 million, with 746 systems placed versus 862 a year earlier, a decline of about 13.4% in units. Management signaled that they do not anticipate an immediate rebound, with softness in placements expected to persist into Q2 before any potential commercial improvements are felt.

Consumables Pressure, Especially in APAC

Consumables revenue declined 6.1% to $46.4 million, pressured by weaker utilization trends and regional challenges. In APAC, consumables dropped 29.9%, largely due to the ongoing transition in China to a distributor model, which continues to distort year‑over‑year comparisons and weigh on segment growth.

Structural Macro and Competitive Headwinds

Management pointed to tighter credit conditions and longer capital purchasing cycles as dampening demand for higher‑ticket aesthetic equipment. They also highlighted intensifying competition, including lower‑cost and secondary‑market devices, and a maturing market, all of which are combining to cap near‑term growth potential in device sales.

Normalized Margin Expectations and One-Time Benefits

Q1 gross margin benefited from higher‑than‑expected device average selling prices in the Americas and unusually low scrap and write‑offs. Executives warned that these factors are not likely to repeat, and they expect gross margin to step down from Q1 levels, though they still see a solid margin profile going forward.

Near-Term Execution Risk and Commercial Fixes

The company is rolling out commercial fixes, including tighter sales processes, improved pipeline management and leadership changes, aiming to reinvigorate growth. However, management stressed that these actions will take time to translate into revenue, and their outlook assumes 2026 is a stabilization year with more dependable growth emerging in 2027.

Guidance and Outlook

For 2024, Beauty Health now guides revenue to $280 million to $295 million while reiterating adjusted EBITDA of $35 million to $45 million, signaling confidence in profitability despite lower sales. Q2 revenue is expected between $72 million and $77 million with adjusted EBITDA of $11 million to $13 million, while the company targets modest positive free cash flow over the final three quarters and flat working capital.

Beauty Health’s earnings call ultimately balanced caution with measured optimism. Revenue and device placements are under pressure and sector headwinds are real, but margins, cash and the installed base are moving in the right direction. For investors, the story now hinges on execution of commercial fixes and innovation, with 2027 positioned as the year when those efforts should begin to fully pay off.